Unraveling Osteoporosis Treatment Market Potential: Current ScenarioPosted by Roger on January 12th, 2024 Osteoporosis is a skeletal disorder characterized by low bone mass and deterioration of bone tissue, leading to increased risk of fractures. It majorly affects elderly people and is common in both men and women with an increase in age. The rising geriatric population is one of the major drivers boosting the growth of the osteoporosis treatment market. According to the United Nations, there were approximately 703 million people aged 65 years and above worldwide in 2019 and this number is projected to reach 1.5 billion by 2050. With growing aging demographics, the prevalence of osteoporosis and risk of fractures are anticipated to rise significantly which in turn is projected to drive the demand for osteoporosis drugs and devices over the forecast period. Growing Geriatric Population Threat of new entrants: Low capital requirements but intellectual property protection, high R&D costs for new drugs and long approval timelines pose moderate barriers. Bargaining power of buyers: Large healthcare providers and pharmacy chains have strong bargaining power to negotiate prices and control costs. Bargaining power of suppliers: A few large pharmaceutical companies control supply of branded osteoporosis drugs giving them significant bargaining power. Threat of new substitutes: Drugs targeting similar disease pathways pose some threat but patents also provide protection against new substitutes. Competitive rivalry: Intense rivalry between large pharma companies to introduce new and improved drugs or newer drug delivery mechanisms. Strength: Drugs like Fosamax, Actonel and Protelos are top-selling branded products. Established brands have recognition and market share. Weakness: High cost of branded drugs leads to low compliance and uptake rates. Complex administration routes like injections impact adherence negatively. Opportunity: Untapped developing markets especially China and India offer huge market potential. New anabolic drugs like romosozumab can drive next phase of growth. Threats: Loss of patents opens door for cheap generics. Biosimilars of Prolia and Xgeva also pose pricing pressure once approved. The global osteoporosis treatment market is expected to witness high growth led by fast aging demographics and rise in post-menopausal osteoporosis cases globally. Regional analysis: North America currently dominates the market due to high healthcare expenditures and easy access to branded drugs. However, Asia Pacific region is poised to grow at fastest CAGR through 2030 led by China, Japan and India due to changing lifestyles. Key players: Key players operating in the osteoporosis treatment market are Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy’s Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co., Inc., GSK plc., and Pfizer Inc. Largest osteoporosis drugs by sales are Fosamax, Actonel, Protelos and Prolia. Like it? Share it!More by this author |